摘要
激素非依赖前列腺癌是前列腺癌的终末阶段，雄激素剥夺的内分泌治疗效果差，而雌二醇氮芥和紫杉醇为主的化疗能够明显的提高PSA缓解率、延长患者的生存时间，第三代的双磷酸盐唑来磷酸能够缓解骨转移的疼痛及减少骨转移引起的骨折等并发症，基因及免疫治疗是治疗激素非依赖前列腺癌的新方法。
出处
《中国临床实用医学》
2010年第3期255-257,共3页
China Clinical Practical Medicine
参考文献7
-
1Chodak GW, Keane T, Klotz L, et al. Critical evaluation of hormonal therapy for carcinoma of the p rostate. Urology ,2002,60:201-208.
-
2CampbeU-Walsh Urology. Treatment of Hormone-Refractory Prostate. Cancer, 2007,9 ( 10 ).
-
3Kraus L A, Samuel S K, Schmid S M, et al. The mechanism of action of docetaxel ( Taxotere ) in xenograftmodels is not limited to BCL-2-2 phosphorylation. Invest New Drugs,2003,21:259-268.
-
4王荫槐,张选志,赵小昆,杨罗艳,刘任.磷酸雌二醇氮芥联合非那雄胺治疗激素难治性前列腺癌疗效观察[J].中国肿瘤临床与康复,2007,14(5):461-463. 被引量：2
-
5Campbell-Walsh Urology. 9th ed, Chapter 105-Treatment of Hormone-Refractory Prostate Cancer. Table 105-3,105-4.
-
6Beer T M, Eilers K M, Garzotto M, et al. Weekly highdose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin onco1,2003,21 : 123-128.
-
7Sand F, Gleason DM, Murry R, et al. A randomized placebo controlled trial of zoledronic acid in patients wihormone-refractory metastatic prostate carcinoma. J Nail Cancer,2002,94:1458-1468.
二级参考文献13
-
1王亮,陈昭颉,王庆堂,曹文峰,简燚,张秉鸿,汪俊超.非那雄胺对前列腺癌血管形成的影响[J].中华泌尿外科杂志,2005,26(12):809-811. 被引量：3
-
2马建辉.重视实体瘤疗效评价标准的变革——RECIST概要[J].中华泌尿外科杂志,2006,27(2):77-79. 被引量：39
-
3Chodak GW,Keane T,Klotz L,et al.Critical evaluation of hormonal therapy for carcinoma of the prostate[J].Urology,2002,60:201-208.
-
4Schellhammer PE,Venner P,Haas GP,et al.Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalatamide or flutamide in patients receiving combined androgen blockade[J].J Urol,1997,157 (5):1731-1735.
-
5Hirano D,Minei S,Kishimoto Y,et al.Prospective study of esramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy[J].Urol Int,2005,75:43 -49.
-
6Iversen P,Rasmussen F,Asmussen C,et al.Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer:DAPROCA study 9002.Danish Prostatic Cancer Group[J].J Urol,1997,157:529-534.
-
7Petrylak DP.The current role of chemotherapy in metastatic hormone-refractory prostate cancer[J].Urology,2005,65(S5A):3-8.
-
8Koivisto P,Kononen J,Polmberg C,et al.Androgen receptor gene amplification:a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer[J].Cancer Res.1997,57:314-319.
-
9Hobisch A,Culig Z,Radmayr C,et al.Distant metastases from prostatic carcinoma express androgen receptor protein[J].Cancer Res,1995,55:3068-3072.
-
10Donohue JF,Hayne D,Kamik U,et al.Randomized,placebocontrolled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks[J].BJU Int,2005,96(9):1319-1322.
同被引文献30
-
1魏武,葛京平,马宏青,张征宇,高建平.低剂量磷酸雌二醇氮芥在前列腺癌治疗中的应用[J].临床肿瘤学杂志,2007,12(6):432-434. 被引量：4
-
2Sinibaldi VJ.Docetaxel treatment in the elderly patient with hormone refractory prostate cancer[J].Clin Interv Aging,2007,2(4):555-560.
-
3De Dosso S,Berthold DR.Docetaxel in the management of prostate cancer:current standard of care and future directions[J].Expert Opin Pharmacother,2008,9(11):1969-1979.
-
4Hirano D,Minei S,Kishimoto Y,et al.Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen depribation therapy[J].Urol Int,2005,75(1):43-49.
-
5Kitamura T,Suzuki M,Nishimatsu H,et al.Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer[J].Aktuelle Urol,2010,41 (Suppl 1):34-40.
-
6Berry W,Dakhil S,Modiano M.Phase Ⅲ study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer[J].J Urol,2002,168(6):2439-2443.
-
7Thomas C,Hadaschik BA,Thüroff JW,et al.Patients with metastatic hormone-refractory prostate cancer second-line chemotherapy with mitoxantrone plus prednisone[J].Urologe A,2009,48(9):1070-1074.
-
8Bollag DM,McQueney PA,Zhu J,et al.Epothilones:a new class of microtubule stabilizing agents with a taxol-like mechanism of action[J].Cancer Res,1995,55(11):2325-2333.
-
9Goodin S,Kane MP,Rubin EH.Epothilones:Mechanism of action and biologic activity[J].J Clin Oncol,2004,22(10):2015-2025.
-
10Lee JJ,Kelly WK.Epothilones:tubulin polymerization as a novel target for prostate cancer therapy[J].Nat Clin Pract Oncol,2009,6(2):85-92.
二级引证文献3
-
1朱芩,杜文清,程斯倩,沈楠.雄激素抵抗型前列腺癌的治疗现状及进展[J].吉林医药学院学报,2012,33(3):171-176. 被引量：5
-
2齐瑞芳,陈晓东,郭建国,徐继辉,吕军,马宝慧,时静华.Reg Ⅳ蛋白在前列腺癌中的表达及其意义[J].包头医学院学报,2014,30(3):5-6. 被引量：1
-
3吕翠礼.激素耐受性前列腺癌化学治疗40例的护理[J].中国医学装备,2014,11(B12):324-324.
-
1许克新,胡浩,张晓鹏,赵国栋,王晓峰.p21转染对激素非依赖前列腺癌细胞的生长抑制作用[J].中国男科学杂志,2008,22(12):59-61.
-
2王建功,闫天中.皮质醇与雄激素非依赖前列腺癌的关系[J].实用医药杂志,2004,21(7):595-596. 被引量：5
-
3孙颖浩,郎根强,王林辉,高旭,钱松溪,郑家富.联合化疗治疗激素非依赖前列腺癌12例疗效观察[J].临床泌尿外科杂志,2002,17(5):252-253.
-
4卢凯,许斌,陈恕求,张磊,刘春辉,赵宇明,陈明.miR-19a对于去势抵抗性前列腺癌细胞的增殖及凋亡的调控[J].现代医学,2013,41(9):613-616. 被引量：6
-
5虞力航,杨波,王林辉,孙颖浩.维生素E琥珀酸酯对前列腺癌PC-3细胞株的生长抑制和诱导凋亡作用[J].第二军医大学学报,2007,28(9):956-959. 被引量：1
-
6郎根强.前列腺干细胞抗原与前列腺癌[J].国外医学（泌尿系统分册）,2002,22(5):280-282. 被引量：4
-
7郭晔,赵体平.内分泌治疗无效的前列腺癌的口服化疗[J].国外医药（合成药．生化药．制剂分册）,2000,21(6):336-337.
-
8赵强.多西紫杉醇联合雌二醇氮芥治疗晚期雄激素非依赖性前列腺癌22例[J].现代中西医结合杂志,2010,19(18):2291-2292. 被引量：7
-
9孙忠全,钱伟庆,宋建达,徐俊,盛璐,周俊,吴惠兴,谢旦生,汪东亚,丁海雍,张正望,张豪杰.多西他赛加泼尼松3周方案失败后联合雌二醇氮芥治疗激素难治性前列腺癌[J].世界肿瘤杂志,2008,7(1):13-15. 被引量：2
-
10苏雷,李文思,肖黎,秦盛斐,佟明.miRNA-21在激素非依赖前列腺癌细胞系PC3中的表达及对其增殖和侵袭性影响[J].东南大学学报（医学版）,2013,32(5):548-551.
